PRIM-DJ2727

Phase 2Small molecule

TThe University of Texas Health Science Center, Houston

PRIM-DJ2727 is one of 118 small molecule programs targeting Constipation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseActive, not recruiting

Ulcerative ColitisActive, not recruiting

Systemic SclerosisActive, not recruiting

Alcoholic Fatty Liver DiseasePhase 2

Active, not recruiting

Ulcerative ColitisPhase 1

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Velsipity

Pfizer

Phase 3

11 2

Jyseleca

Gilead

Phase 3

6 3

Skyrizi

AbbVie

Phase 3

6 4

Tremfya

Johnson & Johnson

Phase 3

2 5

Orencia

Bristol-Myers Squibb

Phase 3

1 6

Mounjaro

Eli Lilly

Phase 3

1 7

Purinethol

SStason

Phase 3

1 8

Adtralza

LEO Pharma

Phase 3

1 9

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 10

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Ulcerative Colitis

NCT05786404

Phase 2Recruiting

Ulcerative Colitis

NCT04373473

Q2 2028

Phase 2Recruiting

Constipation

NCT06827977

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for PRIM-DJ2727. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRIM-DJ2727 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRIM-DJ2727. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe University of Texas Health Science Center, Houston

PRIM-DJ2727

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Parkinson's Disease2 trials

Ulcerative Colitis2 trials

Alcoholic Fatty Liver Disease1 trial

Clinical Trial1 trial

Constipation1 trial

References

Drug Info

Quick Facts

Related News